Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03074175
Other study ID # XQonc-005
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 1, 2017
Est. completion date December 31, 2019

Study information

Verified date March 2024
Source Xinqiao Hospital of Chongqing
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lung cancer is a malignant tumor that causes the highest morbidity and mortality, and the main pathological type is non-small cell lung cancer (NSCLC). Most of them present with advanced stage at diagnosis. Radiotherapy is an important treatment strategy for advanced non-small cell lung cancer. However patients have different responses to radiotherapy due to individual differences, thus there is still lacking of sensitive markers to predict treatment response at present. Using bioinformatics to process the data and small sample clinical trial, our previous study found 5 plasma miRNAs were related to radiosensitivity. The design is controlled clinical trial. According to the size of lung lesions, the investigators divided the patients into hyperfractionated radiotherapy group(50Gy/11F/2W) with lesion ≤5cm in diameter and conventional fractionated radiotherapy group(60Gy/30F/6W)with lesion >5cm in diameter.


Recruitment information / eligibility

Status Completed
Enrollment 240
Est. completion date December 31, 2019
Est. primary completion date August 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Pathological histology and/or cytology confirmed NSCLC; 2. Based on AJCC Cancer Staging, IIIA, IIIB, IV lung cancer patients with NSCLC; 3. PS 0-2; 4. Expected survival > 3 months; 5. Age 18~75 years old; 6. The function of lung, liver, kidney, bone marrow was normal; 7. The patients had not received radiotherapy for previous primary tumor and metastases; 8. At least accept 2-4 cycles of chemotherapy,not disease progression after chemotherapy,start radiotherapy in two weeks after the last cycle of chemotherapy; 9. Wild-type EGFR; 10. Sensitive mutant EGFR, but refused to targeted therapy; 11. In line with the indications of radiotherapy and accept it; 12. Voluntarily enrolled to participate in,better compliance, cooperate with experimental observations, and sign informed consent. Exclusion Criteria: 1. Vital organs (e.g., heart, liver, kidney) have serious dysfunction; 2. Patients with other malignancies; 3. Patients with a history of autoimmune disease; 4. The patients are pregnant and lactating (Women of childbearing age need to check the pregnancy test); 5. In the activity of acute or chronic infectious diseases; 6. Patients with a clear history of drug allergy or allergic genus; 7. Patients with participating in other clinical trials at the same time; 8. Other cases that researchers believe that patients should not participate in the present trial.

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
radiotherapy
The patient in supine position with hands catch the plate column by crossing the head, and body fixed by vacuum mould. An enhanced 4DCT scan is conducted with a layer thickness and a distance each of 5 mm. the imaging information is input into the Eclipse program system,the gross tumor volume of the primary tumor (GTVt) and pathological lymph nodes (GTVn) are delineated,GTV is expanded in all 3D direction to create PGTV by 5mm margin for squamous cell carcinoma, or an 8mm margin for adenocarcinoma.Radiaion therapy is delivered by 5F-IMRT.For conventional fractionated radiotherapy,the prescribed dose covering 95% of PGTV is 60Gy/30F/6W.For hyperfractionated radiotherapy,the prescribed dose covering 95% of PGTV is 50Gy/11F/2W.lung V20 <25%, lung V30 <18%, spinal cord <36 Gy.

Locations

Country Name City State
China Xinqiao Hospital of Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Xinqiao Hospital of Chongqing

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate(ORR) up to two and a half years
Secondary Correlation between the expression level of miRNAs and the ORR. up to two and a half years
Secondary Progression free survival(PFS) up to two and a half years
Secondary side effects of radiation up to two and a half years
See also
  Status Clinical Trial Phase
Recruiting NCT02133196 - T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT00813332 - Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Phase 4
Completed NCT03215810 - Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Phase 1
Recruiting NCT04982224 - Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer Phase 1/Phase 2
Recruiting NCT05609578 - Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation Phase 2
Not yet recruiting NCT04992858 - Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations Phase 2
Active, not recruiting NCT03127449 - AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations N/A
Not yet recruiting NCT06356675 - A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy Phase 4
Terminated NCT05106335 - A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC Phase 3
Not yet recruiting NCT04229121 - Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
Completed NCT05219162 - Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). Phase 4
Not yet recruiting NCT05859217 - A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) Phase 2
Recruiting NCT03062800 - Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) Phase 2
Completed NCT02055508 - POSITIVE - Study (Part III) Heidelberg N/A
Active, not recruiting NCT04043195 - Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC Phase 1/Phase 2